ArticleScientific reports2025
Comprehensive profiling of plasma and exosomal microRNAs in medication-related osteonecrosis of the jaw.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Proteome and miRNAs Expression in Medication-Related Osteonecrosis of the Jaw.International journal of molecular sciences · 2026Article
- Screening of Salivary Biomarkers of Bisphosphonate-Related Osteonecrosis of the Jaw in a Diabetic Rat Model.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The role of circulating microRNAs (miRNAs) in the pathophysiology of medication-related osteonecrosis of the jaw (MRONJ) remains to be elucidated. This study investigated the expression of plasma miRNAs in patients with MRONJ compared to healthy individuals. 16 patients with MRONJ and 15 healthy controls participated in this case-control study, which was conducted in three consecutive phases. As a pilot study, miRNA profiling was performed using quantitative real-time reverse transcriptase PCR (qPCR) array plates targeting 754 miRNAs in a subset of plasma samples. In the subsequent phases, individual qPCR assays validated the array results using plasma samples from the full cohort (second phase) and plasma-derived exosomes (third phase). The qPCR arrays revealed differential miRNA profiles between the MRONJ and control groups. We selected miR-153-3p, miR-1180-3p, miR-483-5p, miR-511-5p, miR-628-3p, miR-486-5p, miR-92b-5p, miR-16-3p, miR-23a-3p, and miR-23a-5p for additional assays. The expression of miR-483-5p, miR-92-5p, and miR-486-5p was elevated in patients with MRONJ compared to controls, whereas miR-628-3p was downregulated (q < 0.01). All four miRNAs consistently exhibited differences in expression in plasma-derived exosomes between MRONJ patients and controls. We identified four miRNAs that could serve as potential biomarkers for MRONJ: miR-483-5p, miR-92-5p, miR-628-3p, and miR-486-5p. These biomarkers may reflect key pathways in MRONJ pathogenesis and could be used to guide patient risk stratification and future therapeutic interventions for MRONJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.